Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
Akl Fahed, Interventional Cardiologist and Physician-Scientist at Massachusetts General Hosptal, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC, adding:
“Excited to share our new study presented today at European Society of Cardiology ESC 2026 in Munich and simultaneously published in JACC Journals
Do lifelong differences in LDL cholesterol influence the risk of venous thromboembolism (VTE)?
Prior clinical studies have suggested that lipid-lowering therapies may modestly reduce VTE. But whether this benefit is actually mediated by lowering LDL-C, or by other effects of these therapies, has remained unclear.
We used human genetics as a natural experiment, analyzing sequencing data from more than 700,000 participants in UK Biobank and All of Us.
We examined rare functional variants in LDLR, APOB, and PCSK9 that produce remarkably large, lifelong differences in LDL-C, up to approximately 50 percent.
Despite these profound differences in lifelong LDL-C exposure, we found no consistent association with VTE risk across genes, cohorts, or sensitivity analyses.
Additional common-variant and Mendelian randomization analyses suggest that previously reported associations between LDL-C and VTE may partly reflect obesity and broader metabolic pathways, rather than LDL-C itself.
Take-home: LDL-C itself is unlikely to be a major causal determinant of VTE.
If lipid-lowering therapies reduce VTE, the benefit may involve LDL-independent metabolic, inflammatory, endothelial, or antithrombotic mechanisms, an important distinction for understanding how these therapies work and for identifying future targets for VTE prevention.”
Title: Genetically Mediated Differences in LDL Cholesterol and Risk of Venous Thromboembolism
Authors: Yang Sui, Shinwan Kany, Shaan Khurshid, Kelvin Supriami, Joel T. Rämö, Sean J. Jurgens, Nobuyuki Enzan, Seung Hoan, Zhi Yu, Linke Li, Buu Truong, Xingyu Chen, Min Seo Kim, Injeong Shim, Raphael Twerenbold, James P. Piruccello, Pradeep Natarajan, Patrick T. Ellinor, Akl C. Fahed
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 22, 2026, 14:45Seyed Mehrab Safdari: Prenatal Diagnosis in Hemophilia – Two Decades of Progress and Remaining Challenges
-
Oct 22, 2026, 14:39Mahmoud Abdelnabi: Evaluating the Evidence on Elevated Lp(a) and VTE Before Clinical Translation
-
Oct 22, 2026, 14:34David McIntosh: Fundamental Flaws in National Blood Systems Are Root Causes of Failure
-
Oct 22, 2026, 14:32Aurelio Maggio: Bridging Scientific Progress and Equitable Access to SCD Care in Sub-Saharan Africa
-
Oct 22, 2026, 14:26Khaled Musallam: Longevity and Healthy Aging in Thalassemia
-
Oct 22, 2026, 14:26Deise Catamo Vaz: Two Years of Growth and a New Way of Seeing the World of Stroke
-
Oct 22, 2026, 14:24Yara Mohamed: A Silent Killer Plots his Victim’s Death Over Years
-
Oct 22, 2026, 14:19Shailendra Singh: Two Different Pulmonary Embolism Cases, One Critically Important Lesson
-
Oct 22, 2026, 14:14Caitlin Raymond: Estimating Infection Rates After Therapeutic Plasma Exchange in a Large Real-World Population